GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (LSE:BXP) » Definitions » General and Admin. Expense

Beximco Pharmaceuticals (LSE:BXP) General and Admin. Expense : £4.5 Mil (TTM As of Dec. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Beximco Pharmaceuticals General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Beximco Pharmaceuticals's General and Admin. Expense for the three months ended in Dec. 2024 was £2.3 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2024 was £4.5 Mil.

Beximco Pharmaceuticals General and Admin. Expense Historical Data

The historical data trend for Beximco Pharmaceuticals's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals General and Admin. Expense Chart

Beximco Pharmaceuticals Annual Data
Trend Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.51 3.41 3.93 4.05 4.31

Beximco Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.11 2.02 -1.68 1.85 2.33

Beximco Pharmaceuticals General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £4.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Beximco Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (LSE:BXP) » Definitions » General and Admin. Expense
Comparable Companies
DHA:RENATA DHA:ACMELAB DHA:ORIONINFU DHA:ASIATICLAB DHA:TECHNODRUG DHA:CENTRALPHL DHA:SQURPHARMA ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA SHSE:688506 TSE:4507 BOM:500087
Traded in Other Exchanges
R2WA:Germany BXPHARMA:Bangladesh
Address
19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Website
https://www.beximcopharma.com
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.